Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration
| Autor: | Bianca Fink, Viola Radeck, Bruno Lustinger, Maria-Andreea Gamulescu, Horst Helbig |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Aging medicine.medical_specialty Time Factors genetic structures Bevacizumab Visual Acuity Angiogenesis Inhibitors Antibodies Monoclonal Humanized Macular Degeneration chemistry.chemical_compound Ranibizumab Ophthalmology medicine Humans Intravitreal bevacizumab Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Antibodies Monoclonal Retinal Macular degeneration medicine.disease Fluorescein angiography Exudative age-related macular degeneration eye diseases Surgery Vascular endothelial growth factor chemistry Case-Control Studies Female sense organs Injections Intraocular business medicine.drug |
| Zdroj: | International Ophthalmology. 30:261-266 |
| ISSN: | 1573-2630 0165-5701 |
| Popis: | The purpose of this article is to describe functional and morphological short-term results in patients with exudative age-related macular degeneration (AMD) of all subtypes, treated with intravitreal bevacizumab versus intravitreal ranibizumab. This was a retrospective case-controlled series of 30 patients treated with intravitreal bevacizumab and 30 patients treated with intravitreal ranibizumab for exudative AMD. All patients received three initial injections every 4 weeks. Best corrected visual acuity (BCVA) as well as greatest linear dimension (GLD) of the CNV in fluorescein angiography and central retinal thickness (CRT) in optical coherence tomography (OCT) were monitored 2–4 months after last injection. BCVA stabilized and slightly increased from logMAR 0.74 to 0.62 in the bevacizumab group, and from logMAR 0.76 to 0.58 in the ranibizumab group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink